Alleviating symptoms in patients undergoing long-term hemodialysis : a focus on chronic kidney disease-associated pruritus
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA..
Since the breakthrough of kidney replacement therapy, increases in life expectancy for patients with end-stage kidney disease have been limited. However, patients have become increasingly vocal that, although mortality and life expectancy matter to them, the quality of their life, and particularly the relief of symptoms associated with their treatment, are in many cases more important. The majority of dialysis-associated symptoms and adverse effects do not currently have any approved treatments in this patient population, with the few treatments that are available used off-label, frequently without proven efficacy, yet still potentially adding further adverse effects to patients' current symptom burden. This article will illustrate how understanding the pathophysiology of a single, particularly burdensome symptom of dialysis (chronic kidney disease-associated pruritus) resulted in the design, development and regulatory approval of a treatment for that symptom. The pathway described here can be applied to other symptoms associated with dialysis, meaning that if we cannot add years to patients' lives, we can at least add life to their remaining years.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Clinical kidney journal - 16(2023), 1 vom: 14. Jan., Seite 30-40 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Agarwal, Rajiv [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic kidney disease-associated pruritus |
|---|
| Anmerkungen: |
Date Revised 03.02.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ckj/sfac187 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35236730X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35236730X | ||
| 003 | DE-627 | ||
| 005 | 20231226053548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ckj/sfac187 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM35236730X | ||
| 035 | |a (NLM)36726430 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Agarwal, Rajiv |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Alleviating symptoms in patients undergoing long-term hemodialysis |b a focus on chronic kidney disease-associated pruritus |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.02.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. | ||
| 520 | |a Since the breakthrough of kidney replacement therapy, increases in life expectancy for patients with end-stage kidney disease have been limited. However, patients have become increasingly vocal that, although mortality and life expectancy matter to them, the quality of their life, and particularly the relief of symptoms associated with their treatment, are in many cases more important. The majority of dialysis-associated symptoms and adverse effects do not currently have any approved treatments in this patient population, with the few treatments that are available used off-label, frequently without proven efficacy, yet still potentially adding further adverse effects to patients' current symptom burden. This article will illustrate how understanding the pathophysiology of a single, particularly burdensome symptom of dialysis (chronic kidney disease-associated pruritus) resulted in the design, development and regulatory approval of a treatment for that symptom. The pathway described here can be applied to other symptoms associated with dialysis, meaning that if we cannot add years to patients' lives, we can at least add life to their remaining years | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a chronic kidney disease-associated pruritus | |
| 650 | 4 | |a dialysis | |
| 650 | 4 | |a difelikefalin | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a symptom relief | |
| 700 | 1 | |a Burton, James |e verfasserin |4 aut | |
| 700 | 1 | |a Gallieni, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Kalantar-Zadeh, Kamyar |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer, Gert |e verfasserin |4 aut | |
| 700 | 1 | |a Pollock, Carol |e verfasserin |4 aut | |
| 700 | 1 | |a Szepietowski, Jacek C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical kidney journal |d 2012 |g 16(2023), 1 vom: 14. Jan., Seite 30-40 |w (DE-627)NLM219739579 |x 2048-8505 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:1 |g day:14 |g month:01 |g pages:30-40 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ckj/sfac187 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 1 |b 14 |c 01 |h 30-40 | ||